Our results also argue that the detection of phosphorylated EGFR in conjunction with upregulated expression of an EGF family ligand, particularly TGF-α, a known prognostic factor of poor disease outcome in numerous cancer types,18 may prove an informative criterion of patient stratification when evaluating response to anti-EGFR therapy. The gene discussed is EGF; the disease is cancer.